

بسم الله الرحمن الرحيم

(قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْحَكِيمُ)

(سورة البقرة: ٣٢)

Detection of Topoisomerase II In Hepatocellular Carcinoma Patient Relevant to Chemotherapy Treatment

Thesis Submitted
In partial fulfillment of MD Degree

In
Medical Oncology

By

Rham Zaki Ahmed Mohamed

(M.B., B.ch., (1998) M.S.(2004)
Faculty of Medicine Zagazig University

Under Supervision of

Prof. Dr.

Heba El-Zawahri

*Professor of Medical Oncology
National Cancer Institute
Cairo University*

Prof. DR.

Magda Morad

*Professor of pathology
National Cancer Institute
Cairo University*

Prof. Dr.

Ahmed Abdel Wareth

*Professor of Medical Oncology
National Cancer Institute
Cairo University*

2009

قياس نسبة التوبوايزوميراز-٢ ألفا في مرضى سرطان الكبد وعلاقتها بالعلاج الكيميائي

رسالة مقدمة من

الطبيبة / رهام زكى أحمد محمد

بكالوريوس الطب والجراحة
ماجستير الباطنة العامة

توطئة للحصول على درجة الدكتوراه في طب الأورام

تحت إشراف

الأستاذة الدكتورة/ هبة الظواهرى

أستاذ طب الأورام

المعهد القومى للأورام - جامعة القاهرة

أ.د. أحمد عبد الوارث

أستاذ طب الأورام

المعهد القومى للأورام - جامعة القاهرة

أ.د. ماجدة مراد

أستاذ باثولوجيا الأورام

المعهد القومى للأورام - جامعة القاهرة

Detection of Topoisomerase II In Hepatocellular Carcinoma Patient Relevant to Chemotherapy Treatment

Dr. Heba EL.Zawahry¹, Dr. Magda Morad², Dr. Ahmed Abd Elwareth³

and Rham Zaki Ahmed⁴

Introduction: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide Hepatitis C virus is one of the major causes of chronic liver disease and hepatocellular carcinoma. The most widely used chemotherapeutic agent has been doxorubicin, both as a single agent and in combination with other drugs.

Aim: Determination of Topoisomerase II alpha level in hepatocellular carcinoma patients, evaluation of the response to topoisomerase II alpha inhibitor in hepatocellular carcinoma patients, and evaluation of the relation between the response to chemotherapy and Topoisomerase II alpha.

Methods: Immunohistochemistry was performed to investigate Topoisomerase II alpha expression in 50 HCC tissues and clinicopathological materials were analyzed with statistical methods. Kaplan-Meier method was used to calculate survival curves, and log-rank test was performed to compare differences in survival rates of patients with overexpression with negative results.

Results: the studied marker was detected by IHC in 38% of the patients and the response rate to the doxorubicin was 16% .there was a significant correlation between the overexpression and the response and

the overall survival. There was a significant correlation also between the response and the tumour size, grade, and patient performance status.

Conclusion: The topoisomerase II alpha overexpression has a significant correlation to doxorubicin response and patient survival in hepatocellular carcinoma patients.

Key words: HCC- HCV- chemotherapy-topoisomerase.



Dedication

My work is dedicated to:

My family





ACKNOWLEDGEMENT

Above all and first of all ,praise and thanks must be to *Allah*

Thanks to ***Prof. Dr. Heba El-Zawahary*** Professor of medical oncology, NCI, Cairo University for constant guidance and valuable suggestion during the preparation of this work. I also appreciate her useful remarks and constructive criticism during the critical reading of the manuscript.

I would like to express my profound gratitude and cordial appreciation to ***Prof. Dr., Magda Morad***, Professor of Pathology, NCI, Cairo University, for the encouragement, their kind supervision, continuous support and beneficial remarks that helped me so much to accomplish this work. and ***Prof. Dr. Ahmed Abd El-Wareth***, professor of medical oncology NCI, Cairo University, for his great support.

I wish to thank ***Prof. Dr. Fouad M. Abo Taleb***, Professor of Medical Oncology, Faculty of Medicine, Zagazig University, for his generous help and beneficial remarks.

Finally, I would like to thank all patients and persons who helped me throughout this work.



List of Abbreviations

AFP	Alpha-Fetoprotein
AJCC	American Joint Committee on Cancer
AR	Androgen Receptor
BCLC	Barcelona Clinic Liver Cancer
CAH	Chronic active hepatitis
CDK	Cyclin dependent kinase
CLD	Chronic Liver Disease
CLIP	Cancer of the Liver Italian Program
CPA	Cyproterone Acetate
CR	Complete Response
CRP	C-Reactive Protein
CT	Computed Tomography
CUPI	Chinese University Prognostic Index
DCP	Des-gamma-carboxyl prothrombin
DHT	Dihydrotestosterone
DIC	Disseminated Intravascular Coagulopathy
EGFr	The Epidermal Growth Factor receptor
HAI	Hepatic Artery Infusion
HBSAg	Hepatitis B Surface Antigen
HBV	Hepatitis B Virus
HCC	Hepatocellular Carcinoma
HCV	Hepatitis C Virus
HCVAbs	Hepatitis C Virus Antibodies

JIS	Japan Integrated Staging
LHRH	Luteinizing Hormone Releasing Hormone
LOH	Loss of Heterozygosity
MDR	Multi-Drug Resistance
MELD	Model for end stage liver disease
MRI	Magnetic Resonance Imaging
MsAFP	Monosialyated Alpha-Fetoprotein
OLT	Orthotopic Liver Transplantation
PEI	Percutaneous Ethanol Injection
PIAF	Cisplatin, Interferon alpha-2b, Doxorubicin and 5-Fluorouracil
PMCT	Percutaneous Microwave Coagulation Therapy
Rb	Retinoblastoma
RCV	Reference Change Value
RFA	Radiofrequency Ablation
TACE	Transcatheter Arterial Chemoembolization
US	Ultrasonography

List of Tables

Table number		Page
Table (1)	Chemical Carcinogens Known to Exist in Human Environment	13
Table (2)	child Pugh score	28
Table (3)	modified child Pugh score	28
Table (4)	Tumour marks in hepatocellular carcinoma	34
Table (5)	TNM staging of HCC	50
Table (6)	Okuda staging system	52
Table (7)	Cancer of the liver Italian program staging system	53
Table (8)	Chines university prognostic index (CLIP)	54
Table (9)	Treatment modalites of HCC	60
Table (10)	Okuda staging for HCC	63
Table (11)	Indication for systemic therapy	83
Table (12)	Single agent Response rates for HCC	84
Table (13)	Combination chemotherapy for HCC	85

Table number		Page
Table (14)	Comparison between Topoisomerase I and Topoisomerase II:	95
Table (15)	Patient characteristics of hepatocellular carcinoma	113
Table (16)	Response to doxorubicin treatment	115
Table (17)	The correlation between topoisomerase II alpha Expression and response to the therapy	115
Table (18)	The correlation between the response to therapy and the clininopathological parameters in Hepatocellular carcinoma patients	116
Table (19)	The correlation between clininopathological parameters and topoisomerase II alpha Expression in hepatocellular carcinoma patients	117
Table (20)	Toxicity to chemotherapy	118

List of Figures

Figures Number		Page
Fig. (1)	Haematoxylin&eosin stain section for grade II H.C.C	119
Fig.(2)	Haematoxylin&eosin stain section for grade II H.C.C	119
Fig. (3)	Immunostain section of H.C.C. show focal nuclear positivity of Topoisomerase II alpha (X-200 DAB chromogen)	120
Fig. (4)	Immunostain section of H.C.C. show moderate nuclear positivity of Topoisomerase II alpha(X-200 DAB chromogen)	120
Fig. (5)	Immunostain section of H.C.C. show nuclear as well as cytoplasmic reaction for Topoisomerase II alpha (X-100 DAB chromogen)	121
Fig. (6)	Immunostain section of H.C.C. show focal nuclear reaction for Topoisomerase II alpha (X-400 DAB chromogen)	121
Fig. (7)	Immunostain section of H.C.C. show focal positivity of Topoisomerase II alpha (X-200 DAB chromogen)	122

Figures Number		Page
Fig. (8)	Immunostain section of H.C.C. show focal nuclear positivity of Topoisomerase II alpha (X-400 DAB chromogen)	122
Fig. (9)	Immunostain section of H.C.C. show nuclear as well as cytoplasmic reaction for Topoisomerase II alpha (X-100 DAB chromogen)	123
Fig. (10)	Immunostain section of H.C.C. show nuclear as well as cytoplasmic reaction for Topoisomerase II alpha (X-200 DAB chromogen)	123
Fig. (11)	Immunostain section of H.C.C. show focal nuclear reaction for Topoisomerase II alpha (X-400 DAB chromogen)	124
Fig. (12)	Overall survival in hepatocellular carcinoma patients	125
Fig. (13)	OS in patients with topoisomerase II expression	125

Table (19): The correlation between clininopathological parameters and topoisoemerase II alpha Expression in hepatocellular carcinoma patients

Clinicopathological parameters	Topoisomerase II alpha expression				Total No.	P-value
	- ve		Overexpression			
	No	%	No	%		
Alpha- fetoprotein						
< 400 ng/dl	7	22.6	1	5.3	8	0.13
> 400 ng/dl	24	77.4	18	94.7	42	
Child-pugh class						0.66
A	28	90.3	16	84.2	44	
B	3	9.7	3	15.8	6	
Tumour size						0.23
< 5cm	8	25.8	8	42.1	31	
> 5cm	23	50	11	57.9	19	
Tumour grade						0.04*
Well diff.(I + II)	26	83	15	78	33	
Poor diff(III)	5	16.1	4	21.1	9	
Hepatitis markers:						0.36
HCV	17	54.8	13	68.4	30	
HBV	8	25.8	2	10.5	10	
HBV+HCV	5	16.1	2	10.5	7	
- ve	1	3.2	2	10.5	3	
Sex						0.55
Male	30	96.8	17	89.5	47	
female	1	3.2	2	10.5	3	

* Significant.

Contents

Introduction and Aim of Work	1
Review of Literature	5
- o Chapter (1): - Epidemiology & Etiology. 5 - Hepatocellular Carcinoma in Egypt. 15 - Pathology of Hepatocellular Carcinoma. 19	
- o Chapter (2): - Clinical Presentation & Diagnosis. 23 - Staging & Prognosis. 51 - Screening & prevention 57	
- o Chapter (3): - Treatment. 61 - Topoisomerase II and topoisomerase II inhibitors 97	
Patients and Methods	103
Results	110
Discussion	126
Summary	131
Conclusion and Recommendation	131
Appendix	--
References	135
Arabic Summary	--